David Now Goliath? Made In China PD-1s Sought After By Multinationals
Eager For New Products As Market Evolves
Executive Summary
From relatively little-known to high-flying, hotly pursued targets by global pharma players, Chinese domestically developed immuno-oncology drugs are ascending in both value and attractiveness, both inside China and far beyond.
You may also be interested in...
From China With Discount? BeiGene Moves Towards First Global PD-1 Green Light
Already priced domestically at a deep discount to counterpart PD-1s in the US, Beigene's tislelizumab could potentially get the first global approval for a China-originated drug in this class, as the immuno-oncology sector as a whole continues to come under pressure in China.
China Inc. Shines In Latest Batch Of Approvals
Chinese domestic firms have gained a flurry of novel drug approvals at home, including the first globally for an anti-PD-1 antibody for nasopharyngeal carcinoma.
Asia Deal Watch: Emmaus, Kainos Pursue R&D In Cancers With Limited Therapy Options
Plus deals involving WuXi AppTec/OXGENE, Oscotec/Beatica, ReViral/LianBio, Wugen/HCW Biologics, Starton/Haisco, Shanghai Junshi/AstraZeneca, HitGen/Uppthera, Bridge/LegoChem, Macrogen/Lifex, BeiGene/Boston Immune